Axis Labs, Inc. – Trademark Portfolio
Entity Type: 03
Axis Labs, Inc. holds 23 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 20 filings in this category. The portfolio also extends into Class 9 (Computers & Electronics) across 3 Nice Classification classes. Currently, 6 trademarks are registered. Notable registered marks include RYSE, CLUTCH, XTRACT, AXIS LABS, and HYPERTEST. The owner is based in Englewood, CO.
8200 South Quebec Street A3-120
Englewood, CO 80112
Showing of trademarks Trademarks
Trademark Classifications
Axis Labs, Inc.'s trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments
Advertising; business management; business administration; office functions
Frequently Asked Questions
How many trademarks does Axis Labs, Inc. have?
Axis Labs, Inc. has 23 U.S. trademarks filed with the USPTO. Of these, 6 registered, 5 abandoned, 12 cancelled.
What trademark classes does Axis Labs, Inc. file in?
Axis Labs, Inc. files trademarks across 3 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics), Class 35 (Advertising & Business). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are Axis Labs, Inc.'s most well-known trademarks?
Axis Labs, Inc.'s registered trademark portfolio includes well-known marks such as RYSE, CLUTCH, XTRACT, AXIS LABS, and HYPERTEST. These are among 6 currently registered trademarks in the portfolio.
What is Axis Labs, Inc.'s trademark registration success rate?
Axis Labs, Inc. has a 26% trademark registration rate, with 6 out of 23 resolved applications resulting in successful registration. Currently, 0 applications are pending review.